Stock Performance and Market Context
On 19 Jan 2026, Sanofi Consumer Healthcare India Ltd recorded an intraday low of Rs. 4,017, establishing a fresh 52-week and all-time low. The stock closed with a positive day change of 1.74%, outperforming the sector by 2.28% and the Sensex, which declined by 0.45%. This modest gain followed six consecutive days of declines, signalling a tentative pause in the downward trend.
However, the stock continues to trade below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring persistent weakness in price momentum. Over the past month, the stock has fallen by 8.72%, significantly underperforming the Sensex’s 2.04% decline. The three-month performance shows a 10.47% drop against the Sensex’s marginal 0.90% fall, while the one-year return stands at -14.30%, contrasting sharply with the Sensex’s positive 8.59% gain.
Year-to-date, the stock has declined by 7.43%, compared to the Sensex’s 2.37% fall. Longer-term figures reveal stagnation, with zero growth over three, five, and ten years, while the Sensex has delivered 36.71%, 68.42%, and 239.86% returns respectively over the same periods. This data highlights the stock’s underperformance relative to broader market benchmarks.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Valuation and Financial Metrics
Sanofi Consumer Healthcare India Ltd currently holds a Mojo Score of 43.0 and a Mojo Grade of Sell, downgraded from Hold on 28 Oct 2025. The company’s market cap grade is rated 3, indicating a mid-tier capitalisation within its sector. The downgrade reflects concerns over valuation and profitability trends.
The stock’s valuation appears stretched, with a price-to-book value of 36.9, which is considered very expensive relative to industry norms. Despite a high return on equity (ROE) of 83.6%, the company’s profits have declined by 27% over the past year, contributing to the negative stock returns. This divergence between profitability ratios and market performance suggests investor caution regarding sustainability of earnings.
Management efficiency remains strong, with an average ROE of 76.98%, and the company maintains a low average debt-to-equity ratio of zero, indicating a debt-free balance sheet. These factors provide some stability amid the broader valuation concerns.
Revenue and Profit Trends
Sanofi Consumer Healthcare India Ltd has demonstrated healthy long-term growth in net sales and operating profit. Net sales have grown at an annual rate of 95.70%, while operating profit has increased by 83.94% over the same period. These figures indicate robust top-line expansion and operational profitability on a historical basis.
Quarterly results for September 2025 showed the highest recorded PAT at Rs. 62.90 crores and net sales of Rs. 233.90 crores, representing a 29.2% increase compared to the previous four-quarter average. PBDIT also reached a peak of Rs. 85.00 crores in the quarter. These positive quarterly results contrast with the stock’s overall price weakness, suggesting a complex interplay between financial performance and market valuation.
Shareholding and Market Position
Institutional investors hold a significant 20.16% stake in Sanofi Consumer Healthcare India Ltd. This level of institutional ownership indicates that entities with greater analytical resources maintain exposure to the stock, despite its recent price declines. The company operates within the Pharmaceuticals & Biotechnology sector, which has experienced varied performance amid evolving market conditions.
Holding Sanofi Consumer Healthcare India Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Recent Trends
Sanofi Consumer Healthcare India Ltd’s stock has experienced a sustained period of underperformance relative to both the Sensex and the BSE500 index. The negative returns over one year (-14.30%), three months (-10.47%), and year-to-date (-7.43%) contrast with positive or less severe declines in benchmark indices. The absence of growth over three, five, and ten years further emphasises the stock’s stagnation in comparison to broader market gains.
While the company’s financial metrics such as ROE and sales growth remain strong, the market valuation and profit contraction have weighed on the stock price. The recent downgrade to a Sell grade by MarketsMOJO on 28 Oct 2025 reflects these concerns.
Today’s slight recovery after multiple days of decline may indicate short-term technical support, but the stock remains below all major moving averages, signalling continued caution among market participants.
Conclusion
Sanofi Consumer Healthcare India Ltd’s fall to an all-time low of Rs. 4,017 marks a notable event in its market journey. Despite solid sales growth and strong management efficiency, the stock’s valuation and profit trends have contributed to its prolonged downtrend. Institutional investors maintain a meaningful stake, reflecting ongoing interest from sophisticated market participants. The stock’s performance relative to key indices and its downgrade to a Sell grade highlight the challenges it faces within the Pharmaceuticals & Biotechnology sector.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
